江苏吴中医药发展股份有限公司 关于股票交易暨退市风险提示公告

Group 1 - The company faces significant delisting risks due to major legal violations as indicated by the administrative penalty notice from the China Securities Regulatory Commission (CSRC) received on July 13, 2025 [3] - The company's stock has been under delisting risk warning since July 14, 2025, following the CSRC's notice, which may lead to mandatory delisting if the formal decision confirms major violations [3] - The company has also encountered financial delisting risks as its 2024 annual financial report received a disclaimer of opinion from the auditing firm, triggering additional delisting risk warnings [4] Group 2 - The company is subject to other risk warnings due to internal control issues in the 2024 financial report and non-operational fund occupation by related parties [5] - The company is currently unable to continue sales of AestheFill due to a breach of contract by Regen Biotech Inc., which has led to arbitration proceedings [6] - The controlling shareholder's entire stake of 122,795,762 shares is under various legal encumbrances, including pledges and judicial freezes, raising further investment risks [6] Group 3 - The company emphasizes the importance of rational investment and urges investors to pay attention to risks, with all official announcements published in designated media [7]